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Mikiro Nakashimab, Tadahiro Nakamuraa, Chikamasa Yamashitac, Hitoshi Sasakia,b and Yukinobu Kodamaa
aDepartment of Hospital Pharmacy, Nagasaki University Hospital, Nagasaki, Japan; bGraduate School of Biomedical Sciences, Nagasaki
University, Nagasaki, Japan; cFaculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan
ABSTRACT
We previously found that a nanoparticle constructed with an antigen, benzalkonium chloride (BK) and
c-polyglutamic acid (c-PGA) showed high Th1 and Th2-type immune induction after subcutaneous
administration. For prophylaxis of respiratory infections, however, mucosal immunity should be
induced. In this study, we investigated the effect of pulmonary administration of a nanoparticle com-
prising ovalbumin (OVA) as a model antigen, BK, and c-PGA on induction of mucosal immunity in the
lungs and serum. The complex was strongly taken up by RAW264.7 and DC2.4cells. After pulmonary
administration, lung retention was longer for the OVA/BK/c-PGA complex than for OVA alone. OVA-
specific serum immunoglobulin (Ig)G was highly induced by the complex. High IgG and IgA levels
were also induced in the bronchoalveolar lavage fluid, and in vivo toxicities were not observed. In con-
clusion, we effectively and safely induced mucosal immunity by pulmonary administration of an OVA/
BK/c-PGA complex.
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Acute respiratory infections almost certainly are the leading
cause of death among children <5-years-old in developing
countries (Williams et al., 2002). Several vaccines, such as
those for influenza, pertussis, and pneumococcus, have been
developed for respiratory infections (White, 1988; Pittman,
1991; Chen et al., 2020). Most of those vaccines are adminis-
tered by the intramuscular and subcutaneous routes, which
could effectively induce serum immunoglobulin (Ig)G.
However, other routes are more useful to stimulate mucosal
immunity for preventing acute respiratory infections.
Mucosal administrations, such as intranasal and pulmonary,
have been reported to effectively induce mucosal IgA and
prevent respiratory infections (Giri et al., 2005; Ainai et
al., 2017).
On the other hand, vaccines for intranasal and pulmonary
administration should not contain adjuvants that have been
reported to cause inflammatory reactions and ulceration at
the administration site (Tamura et al., 1988; McKee et al.,
2007). Another approach for improving the efficacy of vac-
cines without adjuvants is to develop a system that can
effectively deliver vaccines into mucosal antigen-presenting
cells (APCs).
In a previous study, we developed a novel vaccine deliv-
ery vector constructed with an antigen, benzalkonium chlor-
ide (BK) and c-polyglutamic acid (c-PGA). A complex
comprising ovalbumin (OVA) as a model antigen, BK and
c-PGA (OVA/BK/c-PGA complex) effectively delivered OVA
into dendritic cells and improved OVA-specific serum IgG
induction after subcutaneous administration into mice
(Kurosaki et al., 2012). The aim of the present study was to
investigate the effect of pulmonary administration of an
OVA/BK/c-PGA complex on the induction of mucosal immun-
ity in the lungs and serum.
2. Materials and methods
2.1. Chemicals
OVA was purchased from Sigma-Aldrich (St. Louis, MO, USA).
BK was obtained from Nacalai Tesque, Inc. (Kyoto, Japan).
The c-PGA was provided by Yakult Pharmaceutical Industry
Co., Ltd. (Tokyo, Japan). Fluorescein isothiocyanate-labelled
OVA (FITC-OVA) and Alexa Fluor 647-labeled OVA (Alexa647-
OVA) were obtained from Invitrogen (Carls, CA, USA). Fetal
bovine serum (FBS) was purchased from Biological Industries
Ltd. (Kibbutz Beit Haemek, Israel). OPTI-MEM I was obtained
from GIBCO BRL (Grand Island, NY, USA), and a premix
antibiotics solution containing penicillin, streptomycin, and
L-glutamine were obtained from Wako Pure Chemical
Industries, Ltd. (Osaka, Japan). Dulbecco’s Modified Eagle
Medium (DMEM) and RPMI1640 medium were obtained from
Nissui Pharmaceutical Co., Ltd. (Tokyo, Japan).
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2.2. Complex preparation
Previously, we constructed an OVA/BK/c-PGA complex at a
weight ratio of 1:0.2:0.2 (Kurosaki et al., 2012). To prepare
the OVA/BK complex, an appropriate amount of BK solution
(pH 5.0) dissolved in 5% glucose was mixed with OVA solu-
tion (pH 7.0) dissolved in 5% glucose and left for 15minutes
at 4 C. To coat the OVA/BK complex with c-PGA, a c-PGA
solution (pH 7.0) dissolved in 5% glucose was added to the
OVA/BK complex and left for a further 15min at 4 C. The
particle size and f-potential of each complex were measured
by using a Zetasiser Nano ZS (Malvern Instruments, Ltd.,
Malvern, UK).
2.3. Cells
Mouse macrophage cell line RAW264.7 and dendritic cell line
DC2.4 were used. RAW264.7 cells were grown in DMEM sup-
plemented with 10% FBS and antibiotics. DC2.4 cells were
grown in RPMI1640 medium supplemented with 10% FBS,
antibiotics, 1mM non-essential amino acids, and 1 nM 2-mer-
captoethanol. These cells were assessed under a humidified
atmosphere of 5% CO2 in air at 37 C.
2.4. In vitro cellular uptake experiment
RAW264.7 cells and DC2.4 cells were plated onto 24-well
plates (Corning, NY, USA) at a density of 2.0 104 cells/well
and cultivated in 500 mL of culture medium. After 24-h prein-
cubation, the medium was replaced with OPTI-MEM I
medium, and the cells were incubated with 5 mg FITC-OVA
and the complex containing 5 mg FITC-OVA for 2 h. After incu-
bation, those cells were washed with PBS and observed under
a fluorescent microscope (BIOREVO BZ-9000; Keyence Co.,
Osaka, Japan). After observation, those cells were lysed in
300lL of lysis buffer (pH 7.8 and 0.1M Tris/HCl buffer contain-
ing 0.05% Triton X-100 and 2mM EDTA). The lysates were
placed into 96-well plates, and the fluorescence of FITC-OVA
was measured at an emission wavelength of 530 nm with an
excitation wavelength of 480 nm, using a fluorometric micro-
plate reader (Infinite-200Pro M-Plex, Tecan Japan Co., Ltd.,
Kanagawa, Japan). The protein content of the lysate was
determined by a Bradford assay using BSA as a standard.
Absorbance was measured using the microplate reader at
570 nm. Uptake of FITC-OVA was indicated as mg per
mg protein.
2.5. Animals
Animal care and experimental procedures were performed in
accordance with the Guidelines for Animal Experimentation
of Nagasaki University with approval from the Institutional
Animal Care and Use Committee. Male C57BL/6N mice
(5weeks old) were purchased from Japan SLC (Shizuoka,
Japan). After being transported, the mice were allowed to
acclimate to their new environment for 1 day before the
experiments. Pulmonary administration (40 mL) was per-
formed by using a tongue depressor with light by
spontaneous respiration in mice anesthetized by inhalation
of isoflurane (Horiguchi et al., 2015).
2.6. Lung accumulation of complex
In order to examine the accumulation of OVA, the 40 mg
Alexa647-OVA and the complex containing 40 mg Alexa647-
OVA at a volume of 40 mL per mouse were administrated
into mice by pulmonary route. Six days after the administra-
tion, mice were sacrificed and the lungs were dissected. The
fluorescent intensity of Alexa647-OVA in the mouse lung was
observed with a Xenogen IVIS Lumina System coupled with
Living Image software for data acquisition (Xenogen, Co,
Almeda, CA, USA). After the observation, those lungs were
homogenized with lysis buffer and homogenates were centri-
fuged at 15,000 rpm (Kubota-3500, Kubota Corporation,
Tokyo, Japan) for 5min and the fluorescence of Alexa647 in
those supernatants were determined with microplate leader
at an excitation and an emission wavelength of 640 and
670 nm, respectively.
2.7. Immunization
Mice were immunized with a 5% glucose solution, 40 mg
OVA, empty complex of 8 mg BK and 8 mg c-PGA (vehicle)
and OVA/BK/c-PGA complex containing 40 mg OVA by pul-
monary administration, 4 times weekly. Two weeks after the
last immunization, bronchoalveolar lavage fluid (BALF) and
serum were obtained. The BALF and serum were used for
enzyme-linked immunosorbent assay (ELISA) assays.
2.8. Determination of OVA-specific antibodies induction
For OVA coating, 100 mL of OVA solution (10 mg/mL, in 1M
sodium hydrogen carbonate) was added to each well of the
ELISA plates (Thermo Fisher Scientific Inc., Waltham, MA,
USA) and incubated for overnight at 4 C. The plates were
washed three times with phosphate-buffered saline contain-
ing 0.05% Tween-20 (PBST), 200 mL of blocking reagent N
102 (Nichiyu, Co., Ltd., Tokyo, Japan) added to block nonspe-
cific binding and then incubated for 6 h at 4 C. The plates
were washed two times with PBST. Then, 100 mL aliquots of
1000-fold diluted serum and undiluted BALF samples were
added to each well and incubated overnight at 4 C. After
five times washing with PBST, 100 mL each of horseradish
peroxidase (HRP) – conjugated goat anti-mouse IgG, IgA,
IgM, IgE, IgG1, IgG2a, IgG2b and IgG3 (1:10,000) (Abcam,
Cambridge, UK) – were added to each well and incubated at
room temperature for 1 h and then washed five times with
PBST. TMB One solution (Promega, WI, USA) was used and
prepared according to the manufacturer’s instructions. The
reaction was then stopped at 15min by the addition of 1N
hydrochloric acid. Absorbance was read at 450 nm by using
a microplate reader.
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2.9. In vivo toxicity of OVA/BK/c-PGA complex
OVA and OVA/BK/c-PGA complex were administered into
mice by the pulmonary route. BALF was obtained 3 and 24 h
after administration from mice. Twenty-four hours after
administration, the lung was also dissected. Lactate dehydro-
genase (LDH) activity in the BALF was measured using
QuantiChromTM Lactate Dehydrogenase Kit (BioAssay
Systems, CA, USA) according to the manufactory’s instruction.
The lung samples were fixed in a 4% paraformaldehyde
phosphate buffer solution. The sectioning and haematoxylin-
eosin (HE) staining were entrusted to GenoStaff (Tokyo,
Japan). HE-stained sections of the lung were observed by
microscopy at 20magnification.
2.10. Statistical analysis
The statistical significance of differences between the two
groups was assessed by performing Student’s t-test. Multiple
comparisons among the groups were performed by perform-
ing Tukey’s test. p-Values< .05 was considered to be indica-
tive of statistical significance.
3. Results
3.1. Physicochemical properties of the complex
We constructed an anionic OVA/BK/c-PGA complex at a
weight ratio of 1:0.2:0.2. The c-PGA-coated complex had a
Figure 1. Cellular uptake of the FITC-OVA and FITC-OVA/BK/c-PGA complex. RAW264.7 cells (A) and DC2.4 cells (B) were incubated with FITC-OVA and the FITC-
OVA/BK/c-PGA complex. Fluorescent images were acquired by performing fluorescence microscopy at 2 h and cellular uptakes of FITC-OVA were quatified (C). Each
value represents the mean ± S.E. (n¼ 4). p < .01.
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Figure 2. Lung accumulation of Alexa647-OVA after pulmonary administration. Mice were administered Alexa647-OVA or the Alexa647-OVA/BK/c-PGA complex. At
6 days after pulmonary administration, the mice were sacrificed and their lungs dissected. Lung accumulation of Alexa647-OVA was visualized by using a Xenogen
IVIS Lumina System (A) and quantified by using a microplate reader (B). Each value represents the mean ± S.E. (n¼ 4). p < .05 vs. Alexa647-OVA.
Figure 3. OVA-specific antibody in serum after pulmonary administration of the complex. Mice were treated four times with vehicle, OVA and the OVA/BK/c-PGA
complex weekly by pulmonary administration. Two weeks after the last administration, the mice were sacrificed, and serum samples were collected to measure
OVA-specific IgG (A), IgA (B), IgM (C) and IgE (D) by ELISA. The 5% glucose solution was used as the control. Each value represents the mean ± S.E. (n¼ 4–5). p <
.05, p < .01 vs. control, #p < .05, ##p < .01.
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particle size of approximately 105.4 nm and a f-potential of
approximately 35.5mV.
3.2. Cellular uptake of the complex
RAW264.7 cells and DC2.4 cells were treated with FITC-OVA
and FITC-OVA/BK/c-PGA complex, and the cellular uptake of
FITC-OVA was visualized, as shown in Figure 1. FITC-OVA/BK/
c-PGA complex was highly taken by the RAW264.7 cells and
DC2.4 cells, and strong green fluorescence of FITC-OVA was
observed (Figure 1(A,B), respectively). At the same time, little
amounts of FITC-OVA were observed in both cells treated
with FITC-OVA.
Cellular uptakes of FITC-OVA were quantified in the
RAW264.7 cells and DC2.4 cells (Figure 1(C)). FITC-OVA/BK/
c-PGA complex showed significantly higher uptake than the
FITC-OVA in both cells (p< .01).
3.3. Lung accumulation of Alexa647-OVA after
pulmonary administration
Alexa647-OVA and Alexa647-OVA/BK/c-PGA complex were
administered into mice by the pulmonary route to determine
the lung accumulation of Alexa647-OVA as antigen. At 6 days
post-administration, the lungs were dissected, and their
fluorescence intensity was visualized by using a Xenogen
IVIS Lumina System. An ex-vivo fluorescent image is shown
in Figure 2(A). High fluorescence intensity was observed
throughout the whole lung at 6 days after pulmonary admin-
istration, although there was no fluorescence intensity in the
spleen, heart, kidney, and liver (data not shown). Lung accu-
mulation was higher for the Alexa647-OVA/BK/c-PGA com-
plex than for Alexa647-OVA on day 6. As shown in Figure
2(B), lung accumulation was significantly higher for the
Alexa647-OVA/BK/c-PGA complex than for Alexa647-
OVA (p< .05).
3.4. OVA-specific antibody in serum after pulmonary
administration of the complex
A 5% glucose solution, BK/c-PGA complex (vehicle), OVA,
and OVA/BK/c-PGA complex were administered by the pul-
monary route into mice four times, and then serum OVA-spe-
cific IgG, IgA, IgM and IgE were determined by ELISA as
shown in Figure 3. Pulmonary administration of OVA and the
Figure 4. OVA-specific antibody in BALF after pulmonary administration of the complex. Mice were treated four times with vehicle, OVA and the OVA/BK/c-PGA
complex weekly by pulmonary administration. Two weeks after the last administration, the mice were sacrificed, and BALF samples were collected to measure
OVA-specific IgG (A), IgA (B), IgM (C) and IgE (D) by ELISA. The 5% glucose solution was used as the control. Each value represents the mean ± S.E. (n¼ 4–5).p< .01 vs. control, #p < .05, ##p < .01.
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OVA/BK/c-PGA complex increased the IgG levels in mice,
although OVA-specific IgG was not detected in mice adminis-
tered 5% glucose and vehicle. Furthermore, IgG and IgA pro-
duction were significantly higher after administration of the
OVA/BK/c-PGA complex than after administration of OVA
(p< .05 or .01). On the other hand, OVA-specific IgM and IgE
were not induced by OVA or the OVA/BK/c-PGA complex.
3.5. OVA-specific antibody in BALF after pulmonary
administration of the complex
OVA-specific IgG, IgA, IgM and IgE in the BALF were also
determined, as shown in Figure 4. The level of IgG was sig-
nificantly increased by OVA relative to the levels after admin-
istration of the control and vehicle (p< .05 or .01).
Nevertheless, the OVA/BK/c-PGA complex significantly
increased not only IgG but also IgA in the BALF (p< .01).
However, OVA-specific IgM and IgE were not induced by
OVA or the OVA/BK/c-PGA complex.
3.6. IgG subtypes in serum after pulmonary
administration of the complex
Induction effects of OVA-specific IgG subtypes, such as IgG1,
IgG2a, IgG2b and IgG3 in the serum were determined as
shown in Figure 5. Compared with the control and vehicle,
OVA significantly increased only IgG1 (p< .01). The antibody
levels of all subtypes induced by the OVA/BK/c-PGA complex
were significantly higher than the levels induced by the con-
trol and vehicle (p< .05 or .01).
3.7. IgG subtypes in BALF after pulmonary
administration of the complex
OVA-specific IgG subtypes, such as IgG1, IgG2a, IgG2b and
IgG3 in the BALF were also determined, as shown in Figure
6. OVA significantly increased only IgG1 levels relative to
those induced by the control and vehicle (p< .01).
Compared with the control, vehicle, and OVA, the OVA/BK/
Figure 5. IgG subtypes in serum after pulmonary administration of the complex. Mice were treated four times with vehicle, OVA and the OVA/BK/c-PGA complex
weekly by pulmonary administration. Two weeks after the last administration, the mice were sacrificed, and blood samples were collected to measure OVA-specific
IgG1 (A), IgG2a (B), IgG2b (C) and IgG3 (D) in the serum by ELISA. The 5% glucose solution was used as the control. Each value represents the mean ± S.E.
(n¼ 4–5). p < .01 vs. control, #p < .05, ##p < .01.
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c-PGA complex induced significantly higher antibody levels
of all subtypes (p< .05 or .01).
3.8. In vivo toxicity of OVA/BK/c-PGA complex
Mice were administered 5% glucose solution, OVA, and the
OVA/BK/c-PGA complex. LDH activity in the BALF was deter-
mined 3 or 24 h after administration (Figure 7).
Administration of OVA and OVA/BK/c-PGA complex had little
effect on the LDH levels in the BALF.
Twenty-four hours after administration, lungs were dis-
sected from those mice for histological analysis. HE-stained
lung sections are shown in Figure 8. No histological abnor-
malities were observed in the mice treated with OVA and
the OVA/BK/c-PGA complex.
4. Discussion
The lung controls breathing and is exposed to many patho-
gens, such as viruses and bacteria that cause respiratory
infections. Those pathogens infect through the pulmonary
mucosal membrane, so mucosal immunity must be induced
to protect against respiratory infections. To prevent respira-
tory infections, mucosal immunity has an important role;
however, intradermal and intramuscular administration of
the vaccine cannot strongly stimulate mucosal immunity (Ito
et al., 2003; Amorij et al., 2007). The mucosal immune system
that induces secretory IgA is developed on the mucosal sur-
face. Several APCs, such as dendritic cells and macrophages,
have been reported to be located in the mucosal surface
(Kopf et al., 2015). Furthermore, bronchus-associated lymph-
oid tissue (BALT) is found in the bronchiolar mucosa and is a
lymphoid follicle that has a central role in respiratory tract
mucosal immunity (Bienenstock, 1980). Pulmonary adminis-
tration of the vaccine is expected to stimulate the mucosal
immune system effectively. Therefore, we constructed the
OVA/BK/c-PGA complex to assess its usefulness as a vaccine
administered via the pulmonary route.
Figure 4 shows the BALF concentration of OVA-specific
antibodies after pulmonary administration of OVA and the
OVA/BK/c-PGA complex. Pulmonary administration of OVA
Figure 6. IgG subtypes in BALF after pulmonary administration of the complex. Mice were treated four times with vehicle, OVA and the OVA/BK/c-PGA complex
weekly by pulmonary administration. Two weeks after the last administration, the mice were sacrificed, and BALF samples were collected to measure OVA-specific
IgG1 (A), IgG2a (B), IgG2b (C) and IgG3 (D) by ELISA. The 5% glucose solution was used as the control. Each value represents the mean ± S.E. (n¼ 4–5). p < .01
vs. control, #p < .05, ##p < .01.
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increased IgG but had little effect on IgA in BALF. On the
other hand, the OVA/BK/c-PGA complex significantly induced
IgA secretion in the BALF. Furthermore, serum IgG induction
was significantly higher after administration of the OVA/BK/
c-PGA complex than after administration of OVA (Figure 3).
Serum IgG is important for preventing aggravation of any
infections that occur (Huber et al., 2006; Schroeder &
Cavacini, 2010). The results indicate that the OVA/BK/c-PGA
complex could prevent respiratory infections by high muco-
sal IgA induction and aggravation of respiratory infection by
high serum IgG induction. Furthermore, IgE induction by the
OVA/BK/c-PGA complex was not observed, and this result
indicated little risk of allergic reaction by the OVA/BK/
c-PGA complex.
The OVA/BK/c-PGA complex could also induce not only
IgG1 and IgG2b but also IgG2a and IgG3 (Figure 5). IgG1 and
IgG2b are known as Th2-type immunoglobulins that mediate
the humoral immune response, and IgG2a and IgG3 are
known as Th1-type immunoglobulins that mediate the cellu-
lar immune response (Firacative et al., 2018). Therefore, the
OVA/BK/c-PGA complex could induce both the humoral and
cellular immune responses. These results suggest that this
system could be useful for vaccines against infections as well
as cancers. The preventive effect, antigen-induced Th1- and
Th2-type cytokine responses in inducible BALT, Treg popula-
tion, and IL-10 induction should be assessed using real anti-
gens from infections or cancers in future studies.
The strong induction by the OVA/BK/c-PGA complex of
the immune response must be due to the high retention
of the complex in the lung and effective delivery of OVA
into the APCs in the pulmonary mucosa. Our results con-
firmed this by showing that 6 days after administration, the
Alexa647-OVA/BK/c-PGA complex still remained in the lung
and showed significantly higher fluorescence than Alexa647-
OVA (Figure 2). The complex formation might prevent diffu-
sion of OVA and protect OVA from degradation by proteases
in the pulmonary mucosa. Furthermore, the OVA/BK/c-PGA
complex was able to effectively deliver OVA into RAW264.7
macrophage cells and DC2.4 dendritic cells (Figure 1). Those
results indicated that the OVA/BK/c-PGA complex would be
taken up by alveolar APCs and induce a high immune
response after pulmonary administration. It has been
reported that c-PGA–coated nanoparticles were taken up by
the gamma-glutamyl transpeptidase-mediated endocytotic
pathway (Du et al., 2015). We also confirmed the
c-PGA–coated nanoparticles were taken up by the c-PGA
specific endocytotic pathway (Kurosaki et al., 2009). The
OVA/BK/c-PGA complex might be taken up by APCs in the
Figure 7. LDH level in the BALF after pulmonary administration of 5% glucose,
OVA and the OVA/BK/c-PGA complex. Five percent glucose solution, OVA and
the OVA/BK/c-PGA complex were administered to mice. Three and twenty-four
hours after administration (A and B, respectively), BALF was taken from the
mice and LDH activity in the BALF was determined. Each value represents the
mean ± S.E. (n¼ 4).
Figure 8. Lung micrograph after pulmonary administration of 5% glucose (A), OVA (B) and the OVA/BK/c-PGA complex (C). Five percent glucose solution, OVA and
the OVA/BK/c-PGA complex were administered to mice. Twenty-four hours after administration, the mice were sacrificed and their lungs dissected. HE-stained sec-
tions of the lung were observed by microscopy at 20 magnification.
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lung through the same mechanisms. However, it is still not
clear that which cells are responsible for OVA-uptake and
subsequent antigen presentation in the induction of specific
immunity. Further studies about detailed immune induction
mechanisms should be performed in the future.
Many adjuvants have been developed to enhance the
effectiveness of vaccines; however, adjuvants have been
reported to cause inflammatory reactions at the injection site
(Tamura et al., 1988; McKee et al., 2007). Therefore, adminis-
tration of adjuvants to the lung might cause severe side
effects, such as pneumonia. After pulmonary administration
of the OVA/BK/c-PGA complex, LDH levels in the BALF were
not increased (Figure 7) and histological abnormalities were
not observed in the HE-stained section (Figure 8).
Reportedly, c-PGA is a biocompatible and biodegradable
polymer that does not show immuno-inflammatory reactions
(Prodhomme et al., 2003; Ye et al., 2006). BK is a safe quater-
nary ammonium compound that has been widely used clinic-
ally as an antimicrobial additive (Marple et al., 2004). These
reports also support the safety of the OVA/BK/c-PGA com-
plex. On the other hand, higher LDH levels were observed at
3 h after the pulmonary administration than at 24 h, even in
the control group. Those results are indicating that a slight
irritation was caused by pulmonary administration. Further
safety studies are needed before clinical application of the
OVA/BK/c-PGA complex.
In the present study, we demonstrated high mucosal
immune system induction by a novel vaccine delivery vector
constructed with an antigen protein, BK, and c-PGA after pul-
monary administration. The system can be used for vaccines
against various respiratory infections.
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